Cargando…
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
Currently most attempts at cancer immunotherapy involve the generation of CD8(+) cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed....
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193835/ https://www.ncbi.nlm.nih.gov/pubmed/12566422 http://dx.doi.org/10.1084/jem.20021683 |
_version_ | 1782147563375296512 |
---|---|
author | Mattes, Joerg Hulett, Mark Xie, Wei Hogan, Simon Rothenberg, Marc E. Foster, Paul Parish, Christopher |
author_facet | Mattes, Joerg Hulett, Mark Xie, Wei Hogan, Simon Rothenberg, Marc E. Foster, Paul Parish, Christopher |
author_sort | Mattes, Joerg |
collection | PubMed |
description | Currently most attempts at cancer immunotherapy involve the generation of CD8(+) cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed. Here we demonstrate that CD4(+) T cells that recognize a secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2 cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma. Clearance of lung metastases by the Th2 cells was found to be totally dependent on the eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the tumors inducing tumor regression. In contrast, tumor-specific CD4(+) Th1 cells, that recruited macrophages into the tumors, had no effect on tumor growth. This work provides the basis for a new approach to adoptive T cell immunotherapy of cancer. |
format | Text |
id | pubmed-2193835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21938352008-04-11 Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process Mattes, Joerg Hulett, Mark Xie, Wei Hogan, Simon Rothenberg, Marc E. Foster, Paul Parish, Christopher J Exp Med Brief Definitive Report Currently most attempts at cancer immunotherapy involve the generation of CD8(+) cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed. Here we demonstrate that CD4(+) T cells that recognize a secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2 cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma. Clearance of lung metastases by the Th2 cells was found to be totally dependent on the eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the tumors inducing tumor regression. In contrast, tumor-specific CD4(+) Th1 cells, that recruited macrophages into the tumors, had no effect on tumor growth. This work provides the basis for a new approach to adoptive T cell immunotherapy of cancer. The Rockefeller University Press 2003-02-03 /pmc/articles/PMC2193835/ /pubmed/12566422 http://dx.doi.org/10.1084/jem.20021683 Text en Copyright © 2003, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Brief Definitive Report Mattes, Joerg Hulett, Mark Xie, Wei Hogan, Simon Rothenberg, Marc E. Foster, Paul Parish, Christopher Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process |
title | Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process |
title_full | Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process |
title_fullStr | Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process |
title_full_unstemmed | Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process |
title_short | Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process |
title_sort | immunotherapy of cytotoxic t cell–resistant tumors by t helper 2 cells: an eotaxin and stat6-dependent process |
topic | Brief Definitive Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193835/ https://www.ncbi.nlm.nih.gov/pubmed/12566422 http://dx.doi.org/10.1084/jem.20021683 |
work_keys_str_mv | AT mattesjoerg immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess AT hulettmark immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess AT xiewei immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess AT hogansimon immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess AT rothenbergmarce immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess AT fosterpaul immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess AT parishchristopher immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess |